Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.42 -0.20 (-0.75%)
Streaming Delayed Price Updated: 2:49 PM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
There could be a light at the end of the tunnel for this beaten-down stock. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
My Top-5 Ultrahigh-Yield Dividend Stocks to Buy in April
Let April showers rain down dividends on you with these great stocks. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
Got $1,000? 2 Phenomenal Growth Stocks to Buy in 2024 and Hold at Least a Decade
These stocks have unique buying propositions for long-term investors. 
Via The Motley Fool
2 Stocks Down 30% and 27% to Buy and Hold
Look beyond these companies' challenges. 
Via The Motley Fool
Better Recovery Story Buy: Pfizer vs Moderna
Pfizer and Moderna each have slipped about 30% over the past year. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
Redditors Discuss What The Top 3 Value Stock Picks Are Right Now
Uncovering value amidst market fluctuations is a quest pursued by many investors. Reddit's r/ValueInvesting community shares insights on top 3 value picks: TSMC, Pfizer, and Berkshire Hathaway. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study
New England Journal of Medicine publishes Pfizer's Paxlovid trial data, revealing insights into COVID-19 treatment efficacy, hospitalization rates, and adverse events. Learn more about the study's... 
Via Benzinga
Exposures COVID-19
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
These stocks could outperform the broad market while they deliver heaps of dividend income. 
Via The Motley Fool
The Comeback Kids: 7 Stocks Ready to Rise from the Ashes
Discover seven resilient comeback stocks thriving across diverse sectors, from pharma to tech, poised for growth amid economic flux. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
Exposures COVID-19
4 Stocks High on My Watchlist to Buy
4 high-quality stocks that need to pullback a bit 
Via The Motley Fool
3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screamings Buys in April
These supercharged dividend stocks -- sporting an average yield of 9.02% -- can pack a punch for income investors' pocketbooks. 
Via The Motley Fool
Unbeatable Blue Chips: 7 Must-Own Stocks for Every Portfolio
Blue chip stocks are excellent wealth builders and a must own for every portfolio of every size and investment style. 
Via InvestorPlace
Three Stocks That Are Set Up For A Great Second Quarter Of 2024
Culling the weak, but holding the strong. 
Via Talk Markets
Blue-Chip Bulldozers: 7 Stock Giants to Plow Through a Wall of Worries
With the smart money diversifying their exposure to risk-on names, now’s the time to consider blue-chip stocks to buy. 
Via InvestorPlace
Jim Cramer Says Chevron Is Doing 'Pretty Well,' Will Give This Pharma Giant 'A Chance'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Core & Main, Inc. (NYSE: CNM) is "right at the heart of this infrastructure bull market I keep talking about because it does waste water. 
Via Benzinga
4 Dividend Aristocrats Trading at a Discount
Near the end of the first quarter, a shift toward more defensive sectors occurred, prompting investors to buy fair-value dividend stocks like MO, T, F, and PFE 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
Healthcare And Biotech Stocks Review: Q1 2024 Performance
We just had one of the best first quarters in recent market history since Q1 in 2019 when the market was up 13%. But changes in sector performance may be coming. The S&P 500 was up 10% showing a slight... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
Viking Therapeutics may be the next company to enter the red-hot weight loss space. 
Via The Motley Fool
Groundbreaking Documentary ‘Project Whistleblower’ Pulls Back the Curtain on Corporate Misconduct
Via Press Release Distribution Service
Topics Whistleblower
Exposures Legal
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.